RE:RE:RE:RE:Gilead's ADC Trodelvy comes up short in ER+/Her2- BCAugust 16, 2022 - When Gilead Sciences acquired Immunomedics in 2020 for USD$ 21 Billion, another company owned certain rights to the deal's crown jewel Trodelvy. Now, Gilead thinks it’s time to take it back.
Gilead is shelling out $280 million upfront to gain Trodelvy rights from Chinese company Everest Medicines in certain Asian territories including China, South Korea, Singapore and others, the two companies said Monday. Everest could also receive up to $175 million in potential regulatory and commercial milestone payments down the line.
[Trodelvy's competition] AstraZeneca and Daiichi Sankyo’s Enhertu is looking to carve out big pieces of the TNBC and HR-positive breast cancer markets further to FDA approval in HER2-low breast cancer, a brand-new category that includes many patients who were traditionally considered HER2-negative.
https://www.fiercepharma.com/pharma/gilead-fresh-china-nod-embraces-trodelvys-asian-rights-455m-deal-everest